Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff P, Higano C, Shore N, Berger E, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff P, Higano C, Shore N, Berger E, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Treating cancer patients with oral medicine versus intravenous chemotherapy results in a 2/3 reduction in hospital time and a greater than 50% reduction in costly medication side effects.  
  • Death rates from breast cancer declined by an average of 2.3% per year between 1990 and 2002 because of earlier detection through screening, better awareness, and improved treatments.  
  • Following the current path, the prostate cancer incidence rate will increase by 75.4% (786,000) between 2003 and 2023. If an alternative path is taken, there will be 21.5% (393,000) fewer…  
  • Five-year Relative Survival (%) during Three Time Periods by Cancer Site  
  • From 2007 to 2011, lung cancer incidence rates decreased by three percent each year in men and 2.2 percent each year in women.